Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.55 |
| ▸ | HTR1B | P28222 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23490734 | 0.86 | HTR1D (0.42) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL7916229 | 0.85 | PRKAB2 (0.48) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL23030468 | 0.83 | HTR1D (0.43) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL23030512 | 0.81 | HTR2A (0.46) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL14827779 | 0.79 | HTR1D (0.57) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL15912345 | 0.79 | HTR1D (0.57) | HTR1DHTR1BHTR2ATP53MAPT | |
| SCHEMBL24172897 | 0.79 | MCL1 (0.41) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL21064332 | 0.78 | NR4A2 (0.39) | HTR1DHTR1BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL22479037 | 0.78 | HTR1D (0.55) | HTR1DHTR1BHTR2APRKAB2PRKAG1 | |
| SCHEMBL15701663 | 0.78 | HTR1D (0.55) | HTR1DHTR1BHTR2APRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | HTR1D 4733/4885HTR1B 4262/4885HTR2A 3606/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | HTR1D 236/4885HTR1B 118/4885HTR2A 97/4885 |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | HTR1D 64/4885HTR1B 72/4885HTR2A 105/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | HTR1D 4782/4885HTR1B 4251/4885HTR2A 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.